We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Hologic Acquires Biolucent

By HospiMedica staff writers
Posted on 01 Oct 2007
Hologic, Inc. More...
(Bedford, MA, USA), a leading provider of diagnostic imaging and state-of-the-art digital imaging systems directed towards women's health, has completed the acquisition of BioLucent, Inc. (Aliso Viejo, CA, USA), the developer and marketer of the MammoPad breast cushion.

"This acquisition reflects our continued strategy and efforts to offer a comprehensive portfolio of products to serve in the breast cancer detection market, ” said Jack Cumming, chairman and chief executive officer. "The BioLucent MammoPad was designed to benefit women undergoing mammograms by providing more comfort, we believe, better tissue acquisition, and ultimately improved outcomes. It is our hope, with proper training and support the MammoPad can become a standard of care in mammography. We look forward to the opportunities that will develop from this combination as we continue to build value for our shareholders.”

BioLucent's MammoPad decreases the discomfort associated with mammography. BioLucent's primary research and development efforts are directed at its brachytherapy business, which is focused on breast cancer therapy. Prior to the acquisition, BioLucent completed the spin-off of its brachytherapy technology and business to the holders of BioLucent's outstanding shares of capital stock. The new company, Cianna Medical, will manufacture and market the SAVI applicator. As a result, Hologic acquired BioLucent's Mammopad business and related assets.

The aggregate purchase price paid by Hologic to the security holders of BioLucent at the closing of the acquisition, exclusive of certain transaction costs and expenses, was approximately US$70 million, of which amount $65 million was paid by Hologic in shares of Hologic's common stock.

"We are pleased we have finalized this agreement with Hologic,” said Steven Gex, president and CEO of Biolucent, Inc. "We believe Hologic's experience and ability to work with partners to drive the adoption of value-added products in the sales channel will serve as the perfect compliment to our MammoPad breast cushion.”

Hologic is a leading developer, manufacturer, and supplier of medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of digital imaging technology for general radiography and mammography applications. Hologic's core business units are focused on osteoporosis assessment, mammography, and breast biopsy, direct-to-digital X-ray for general radiography applications, and mini C-arm imaging for orthopedic applications.


Related Links:
Hologic
Biolucent

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Heavy-Duty Wheelchair Scale
6495 Stationary
Gold Member
Electrode Solution and Skin Prep
Signaspray
Critical Care Conversion Kit
Adapter+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.